Moreover, no data were available on tumor sidedness or other potential prognostic or predictive molecular markers, such as the status of microsatellite instability, BRAF, or HER2. Limitations also apply to the model building, which is affected by the absence of postprogression measurements. This evidence concerns the gene ERBB2 and neoplasm.